EGFR Exon 20 Mutation clinical trials at UC Davis
1 research study open to eligible people
open to eligible people ages 18 years and up
CLN-081-101 is a Phase 1/2a, open label, multi-center study of CLN-081 in patients with NSCLC (non small cell lung cancer) harboring EGFR (epidermal growth factor receptor) exon 20 insertion mutations, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
Sacramento, California and other locations
Our lead scientists for EGFR Exon 20 Mutation research studies include Jonathan W Riess, MD, MS.